30 related articles for article (PubMed ID: 36941031)
1. Effects of Teriparatide Treatment on Bone Mineral Density in Patients With Osteoporosis: A Short-Term Dose-Response Study.
Roy AN; Mazumdar I
Cureus; 2023 Sep; 15(9):e45662. PubMed ID: 37868433
[TBL] [Abstract][Full Text] [Related]
2. Effects of teriparatide on bone in autochthonous transgenic model mice for diabetes mellitus (Akita mice).
Ohuchi K; Miyakoshi N; Kasukawa Y; Segawa T; Kinoshita H; Sato C; Fujii M; Shimada Y
Osteoporos Sarcopenia; 2019 Dec; 5(4):109-115. PubMed ID: 31938729
[TBL] [Abstract][Full Text] [Related]
3. Causal associations of brain structure with bone mineral density: a large-scale genetic correlation study.
Guo B; Wang C; Zhu Y; Liu Z; Long H; Ruan Z; Lin Z; Fan Z; Li Y; Zhao S
Bone Res; 2023 Jul; 11(1):37. PubMed ID: 37474577
[TBL] [Abstract][Full Text] [Related]
4. Long-term and sequential treatment for osteoporosis.
Foessl I; Dimai HP; Obermayer-Pietsch B
Nat Rev Endocrinol; 2023 Sep; 19(9):520-533. PubMed ID: 37464088
[TBL] [Abstract][Full Text] [Related]
5. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
Cosman F
Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis.
Mochizuki T; Yano K; Ikari K; Okazaki K
J Bone Miner Metab; 2023 Mar; 41(2):220-226. PubMed ID: 36625920
[TBL] [Abstract][Full Text] [Related]
8. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
9. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs.
Song J; Jin Z; Chang F; Li L; Su Y
Med Sci Monit; 2014 Dec; 20():2624-32. PubMed ID: 25503108
[TBL] [Abstract][Full Text] [Related]
10. Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.
Kong M; Gao C; Luan X; Fan C; Hao M; Jin C; Zhao J; Li H; Zhao J; Luan J; Lin Y; Li Q
BMC Musculoskelet Disord; 2024 Feb; 25(1):109. PubMed ID: 38310278
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy.
Alonso N; Albagha OME; Azfer A; Larraz-Prieto B; Berg K; Riches PL; Ostanek B; Kocjan T; Marc J; Langdahl BL; Ralston SH
Ann Rheum Dis; 2023 Jul; 82(7):985-991. PubMed ID: 36941031
[TBL] [Abstract][Full Text] [Related]
12. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
Hong P; Liu R; Rai S; Liu J; Zhou Y; Zheng Y; Li J
J Orthop Surg Res; 2023 Feb; 18(1):116. PubMed ID: 36797767
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
